Jonathon B. Cohen, MD, MS

Articles by Jonathon B. Cohen, MD, MS

Next Steps in Relapsed/Refractory Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

BTK Inhibitors in MCL: Long-Term Safety & Efficacy Data

ByJonathon B. Cohen, MD, MS
May 18th 2020

BTK Inhibitor Toxicities in Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

Administration of BTK Inhibitors for Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

Relapsed Mantle Cell Lymphoma Treatment Landscape

ByJonathon B. Cohen, MD, MS
May 18th 2020

Initiating Therapy for Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

Diagnosing MCL and Making Informed Treatment Decisions

ByJonathon B. Cohen, MD, MS
May 18th 2020

Case Assessment: 68-Year-Old Patient With MCL

ByJonathon B. Cohen, MD, MS
May 18th 2020

A 68-Year-Old Man With Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

Recommendations for treating a 68-year-old male with mantle cell lymphoma with a BTK inhibitor once he has relapsed on prior therapy.

Latest Updated Articles

  • Case Assessment: 68-Year-Old Patient With MCL
    Case Assessment: 68-Year-Old Patient With MCL

    May 18th 2020

  • Relapsed Mantle Cell Lymphoma Treatment Landscape
    Relapsed Mantle Cell Lymphoma Treatment Landscape

    May 18th 2020

  • Diagnosing MCL and Making Informed Treatment Decisions
    Diagnosing MCL and Making Informed Treatment Decisions

    May 18th 2020

  • Administration of BTK Inhibitors for Mantle Cell Lymphoma
    Administration of BTK Inhibitors for Mantle Cell Lymphoma

    May 18th 2020

  • Initiating Therapy for Mantle Cell Lymphoma
    Initiating Therapy for Mantle Cell Lymphoma

    May 18th 2020

  • BTK Inhibitor Toxicities in Mantle Cell Lymphoma
    BTK Inhibitor Toxicities in Mantle Cell Lymphoma

    May 18th 2020